294 related articles for article (PubMed ID: 28982208)
61. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
62. Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer.
Pericay C; Serra-Aracil X; Ocaña-Rojas J; Mora-López L; Dotor E; Casalots A; Pisa A; Saigí E
Clin Transl Oncol; 2016 Jul; 18(7):666-71. PubMed ID: 26497352
[TBL] [Abstract][Full Text] [Related]
63. Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Pacelli F; Sanchez AM; Covino M; Tortorelli AP; Bossola M; Valentini V; Gambacorta MA; Doglietto GB
Am Surg; 2013 Feb; 79(2):151-61. PubMed ID: 23336654
[TBL] [Abstract][Full Text] [Related]
64. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Klautke G; Küchenmeister U; Foitzik T; Ludwig K; Semrau S; Prall F; Klar E; Fietkau R
Radiother Oncol; 2007 Dec; 85(3):379-84. PubMed ID: 18036687
[TBL] [Abstract][Full Text] [Related]
65. Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
Lu JY; Xiao Y; Qiu HZ; Wu B; Lin GL; Xu L; Zhang GN; Hu K
J Surg Oncol; 2013 Sep; 108(4):213-9. PubMed ID: 23913795
[TBL] [Abstract][Full Text] [Related]
66. Have the changes in treatment of rectal cancer made a significant difference to our patients?
Benson AB; Guillem JG; Minsky BD
Oncology (Williston Park); 2011 Dec; 25(14):1323-9. PubMed ID: 22329182
[TBL] [Abstract][Full Text] [Related]
67. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
68. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
69. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial.
Golo D; But-Hadzic J; Anderluh F; Brecelj E; Edhemovic I; Jeromen A; Omejc M; Oblak I; Secerov-Ermenc A; Velenik V
Radiol Oncol; 2018 Sep; 52(3):267-274. PubMed ID: 30210040
[TBL] [Abstract][Full Text] [Related]
70. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
71. Oncological outcomes in extended time intervals betweenpreoperative chemoradiotherapy with capecitabine and surgery inoperable rectal adenocarcinoma.
Muñoz MA; Palacios MG; Malca J; Mantilla R; Montenegro PC; Chavez I
Rev Gastroenterol Peru; 2018; 38(1):9-21. PubMed ID: 29791416
[TBL] [Abstract][Full Text] [Related]
72. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.
Dolinsky CM; Mahmoud NN; Mick R; Sun W; Whittington RW; Solin LJ; Haller DG; Giantonio BJ; O'Dwyer PJ; Rosato EF; Fry RD; Metz JM
J Surg Oncol; 2007 Sep; 96(3):207-12. PubMed ID: 17443718
[TBL] [Abstract][Full Text] [Related]
73. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Akgun Z; Saglam S; Yucel S; Gural Z; Balik E; Cipe G; Yildiz S; Kilickap S; Okyar A; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2014 Oct; 74(4):751-6. PubMed ID: 25102935
[TBL] [Abstract][Full Text] [Related]
74. Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: prognostic significance.
Gomez-Millan J; Perez L; Aroca I; Del Mar Delgado M; De Luque V; Román A; Torres E; Ramos S; Perez S; Bayo E; Medina JA
BMC Cancer; 2014 Mar; 14():192. PubMed ID: 24629143
[TBL] [Abstract][Full Text] [Related]
75. Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Terzi C; Bingul M; Arslan NC; Ozturk E; Canda AE; Isik O; Yilmazlar T; Obuz F; Birkay Gorken I; Kurt M; Unlu M; Ugras N; Kanat O; Oztop I
Colorectal Dis; 2020 Mar; 22(3):279-288. PubMed ID: 31566843
[TBL] [Abstract][Full Text] [Related]
76. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
[TBL] [Abstract][Full Text] [Related]
77. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
[TBL] [Abstract][Full Text] [Related]
78. Analysis of clinical outcomes and prognostic factors of neoadjuvant chemoradiotherapy combined with surgery: intraperitoneal versus extraperitoneal rectal cancer.
Benzoni E; Terrosu G; Bresadola V; Cerato F; Cojutti A; Milan E; Dado G; Bresadola F
Eur J Cancer Care (Engl); 2006 Jul; 15(3):286-92. PubMed ID: 16882126
[TBL] [Abstract][Full Text] [Related]
79. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer.
Li N; Dou L; Zhang Y; Jin J; Wang G; Xiao Q; Li Y; Wang X; Ren H; Fang H; Wang W; Wang S; Liu Y; Song Y
Gastrointest Endosc; 2017 Mar; 85(3):669-674. PubMed ID: 27354104
[TBL] [Abstract][Full Text] [Related]
80. Improving chemoradiotherapy in rectal cancer.
Glynne-Jones R; Debus J
Oncologist; 2001; 6 Suppl 4():29-34. PubMed ID: 11585972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
